These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 35533739)

  • 1. Immunomodulatory and immunosuppressive therapies in cardiovascular disease and type 2 diabetes mellitus: A bedside-to-bench approach.
    Mikkelsen RR; Hundahl MP; Torp CK; Rodríguez-Carrio J; Kjolby M; Bruun JM; Kragstrup TW
    Eur J Pharmacol; 2022 Jun; 925():174998. PubMed ID: 35533739
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expert Group Consensus Opinion: Role of Anti-inflammatory Agents in the Management of Type-2 Diabetes (T2D).
    Das AK; Kalra S; Tiwaskar M; Bajaj S; Seshadri K; Chowdhury S; Sahay R; Indurkar S; Unnikrishnan AG; Phadke U; Pareek A; Purkait I
    J Assoc Physicians India; 2019 Dec; 67(12):65-74. PubMed ID: 31801334
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Role of Suppressing Inflammation in the Treatment of Atherosclerotic Cardiovascular Disease.
    Roman YM; Hernandez AV; White CM
    Ann Pharmacother; 2020 Oct; 54(10):1021-1029. PubMed ID: 32425120
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting Inflammation to Reduce Residual Cardiovascular Risk.
    Ajala ON; Everett BM
    Curr Atheroscler Rep; 2020 Sep; 22(11):66. PubMed ID: 32880743
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined treatment with interleukin-1 and tumor necrosis factor-alpha antagonists improve type 2 diabetes in rats.
    DiK B; Bahcivan E; Eser Faki H; Uney K
    Can J Physiol Pharmacol; 2018 Aug; 96(8):751-756. PubMed ID: 29558631
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The efficacy of inhibiting tumour necrosis factor alpha and interleukin 1 in patients with rheumatoid arthritis: a meta-analysis and adjusted indirect comparisons.
    Nixon R; Bansback N; Brennan A
    Rheumatology (Oxford); 2007 Jul; 46(7):1140-7. PubMed ID: 17478472
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials.
    Moran A; Bundy B; Becker DJ; DiMeglio LA; Gitelman SE; Goland R; Greenbaum CJ; Herold KC; Marks JB; Raskin P; Sanda S; Schatz D; Wherrett DK; Wilson DM; Krischer JP; Skyler JS; ; Pickersgill L; de Koning E; Ziegler AG; Böehm B; Badenhoop K; Schloot N; Bak JF; Pozzilli P; Mauricio D; Donath MY; Castaño L; Wägner A; Lervang HH; Perrild H; Mandrup-Poulsen T;
    Lancet; 2013 Jun; 381(9881):1905-15. PubMed ID: 23562090
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipid profile of rheumatoid arthritis patients treated with anti-tumor necrosis factor-alpha drugs changes according to disease activity and predicts clinical response.
    Cacciapaglia F; Anelli MG; Rinaldi A; Serafino L; Covelli M; Scioscia C; Iannone F; Lapadula G
    Drug Dev Res; 2014 Nov; 75 Suppl 1():S77-80. PubMed ID: 25381986
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk and severity of herpes zoster in patients with rheumatoid arthritis receiving different immunosuppressive medications: a case-control study in Asia.
    Liao TL; Chen YM; Liu HJ; Chen DY
    BMJ Open; 2017 Jan; 7(1):e014032. PubMed ID: 28057661
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atherothrombosis Prevention and Treatment with Anti-interleukin-1 Agents.
    Biondi-Zoccai G; Garmendia CM; Abbate A; Giordano A; Frati G; Sciarretta S; Antonazzo B; Versaci F
    Curr Atheroscler Rep; 2020 Jan; 22(1):4. PubMed ID: 31932973
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapies in rheumatologic disorders.
    Miller AV; Ranatunga SK
    Med Clin North Am; 2012 May; 96(3):475-96, ix-x. PubMed ID: 22703852
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of Interleukin-1 in the Treatment of Selected Cardiovascular Complications.
    Heydari FS; Zare S; Roohbakhsh A
    Curr Rev Clin Exp Pharmacol; 2021; 16(3):219-227. PubMed ID: 32674739
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-interleukin-1 treatment in 26 patients with refractory familial mediterranean fever.
    Kucuksahin O; Yildizgoren MT; Ilgen U; Ates A; Kinikli G; Turgay M; Erten S
    Mod Rheumatol; 2017 Mar; 27(2):350-355. PubMed ID: 27328763
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anticytokine Agents: Targeting Interleukin Signaling Pathways for the Treatment of Atherothrombosis.
    Ridker PM
    Circ Res; 2019 Feb; 124(3):437-450. PubMed ID: 30702995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treating inflammation by blocking interleukin-1 in humans.
    Dinarello CA; van der Meer JW
    Semin Immunol; 2013 Dec; 25(6):469-84. PubMed ID: 24275598
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-IL1 treatment in colchicine-resistant paediatric FMF patients: real life data from the HELIOS registry.
    Sag E; Akal F; Atalay E; Akca UK; Demir S; Demirel D; Batu ED; Bilginer Y; Ozen S
    Rheumatology (Oxford); 2020 Nov; 59(11):3324-3329. PubMed ID: 32306038
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Failure of anti Interleukin-1 β monoclonal antibody in the treatment of recurrent pericarditis in two children.
    Signa S; D'Alessandro M; Consolini R; Miniaci A; Bustaffa M; Longo C; Tosca MA; Bizzi M; Caorsi R; Mendonça LO; Pession A; Ravelli A; Gattorno M
    Pediatr Rheumatol Online J; 2020 Jun; 18(1):51. PubMed ID: 32546242
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-interleukin 1 treatment for patients with familial Mediterranean fever resistant to colchicine.
    Ozen S; Bilginer Y; Aktay Ayaz N; Calguneri M
    J Rheumatol; 2011 Mar; 38(3):516-8. PubMed ID: 21159830
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interleukin-1 antagonism moderates the inflammatory state associated with Type 1 diabetes during clinical trials conducted at disease onset.
    Cabrera SM; Wang X; Chen YG; Jia S; Kaldunski ML; Greenbaum CJ; ; Mandrup-Poulsen T; ; Hessner MJ
    Eur J Immunol; 2016 Apr; 46(4):1030-46. PubMed ID: 26692253
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Anti-inflammatory therapy in cardiovascular disease; from hypothesis to future guideline?].
    Hoogeveen RM; Stroes ESG; Cornel JH
    Ned Tijdschr Geneeskd; 2020 Oct; 164():. PubMed ID: 33201620
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.